Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Should we treat high-risk DLBCL differently?

Ulrich Jäger • 12 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Doxorubicin R-CHOP

Ulrich Jäger, MD, of Medical University of Vienna, Vienna, Austria, discusses the critical issue of whether we should treat high-risk diffuse large B-cell lymphoma (DLBCL) differently. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ulrich Jäger

The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
1:23
The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies
Ulrich Jäger • 7 Feb 2025
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
1:32
Results of a Phase II study of parsaclisib for the treatment of primary autoimmune hemolytic anemia
Ulrich Jäger • 7 Feb 2025
Working towards the harmonization of CAR-T registries
1:17
Working towards the harmonization of CAR-T registries
Ulrich Jäger • 7 Feb 2025
The potential role of the tumor microenvironment in CAR T-cell therapy
0:52
The potential role of the tumor microenvironment in CAR T-cell therapy
Ulrich Jäger • 7 Feb 2025

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Ulrich Jäger • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Ulrich Jäger • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Ulrich Jäger • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Ulrich Jäger • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals